Investor Presentation Q1-Q3 2020

23 Investor presentation First nine months of 2020 Continued single digit volume growth within the insulin segments globally Novo NordiskⓇ Long-acting insulin Premix insulin Fast-acting insulin tMU tMU tMU 250 100% 160 100% CAGR volume1: 5.0% MI penetration2: 77.4% CAGR volume1: 1.0% MI penetration²: 47.7% 200 100% CAGR volume1: 4.6% MI penetration²: 80.3% 200 80% 80% 160 80% 120 150 60% 60% 120 60% 100 50 50 88 80 40% 40 20% 40% 80 20% 40 40% 20% 0 0% 0 0% 0 0% Aug Aug Aug 2015 Segment volume Segment volume Aug Aug Segment volume Aug 2020 2015 2020 2015 2020 Ⓡ -NovoMixⓇ30 NovoRapid -Levemir -Tresiba Combined -RyzodegⓇ FiaspⓇ -Combined -Combined 1 CAGR for 5-year period 2 Includes new-generation insulin. tMU: Thousand mega units; NN: Novo Nordisk Note: Modern insulin (MI) penetration is of total segment, i.e. including animal and human insulin; Data is sensitive to changes in IQVIA data collection and reporting methodology. Source: IQVIA MAT, Aug 2020 volume figures

View entire presentation